Zene inc.

Based in Japan, established in 2020, Zene Inc. offers innovative genomic analysis services, enhancing individual health insights through accessible genetic testing solutions. Its flagship product, Zene360, revolutionizes personal health management using genetic information. Zene Inc.

is a Tokyo-based company that specializes in genomic analysis services. It was founded in 2020 and has completed three investment deals to date. The company raised JPY 149 million in its latest funding round on March 8, 2024, with investments from SBI Investment and Spiral Capital. Zene Inc.

has not undergone any pivots in strategy or operations since its inception. The company was founded by a team of individuals, although specific names are not available. The firm's current valuation stands at JPY 1,030. 024 million.

Zene Inc. specializes in advanced genomic analysis services, primarily through its flagship product, Zene360. This service enables users to collect saliva samples conveniently at home for low-cost genetic testing, which provides insights into lifelong genetic information. By visualizing immutable genome data, Zene360 helps users uncover their unique individual traits and health predispositions.

The company targets health insurance unions and municipalities, offering tailored genomic information that aids in preventative health measures and reducing healthcare expenditures. Zene's clientele includes health insurance organizations and research institutions in Japan, focusing on enhancing employee wellness through genomic insights. Zene Inc. generates revenue primarily through its genomic analysis services, structured as direct-to-consumer offerings and partnerships with health insurance providers.

Clients engage in transactions that involve subscriptions for ongoing services or one-time fees for individual genomic analysis, such as the Zene360 service. The pricing structure associated with these services reflects a commitment to affordability while catering to the needs of both consumers and corporate clients. The company emphasizes the value of its genomic insights in transforming healthcare expenses from costs into investments that promote proactive health management. This dual approach bolsters Zene's revenue streams and positions it as a key player in the health and wellness industry in Japan.

In March 2024, Zene Inc. raised JPY 252 million in venture debt funding, which is part of a larger JPY 401 million equity and debt funding round. The company plans to use the funding to stabilize its operational system, strengthen its information management, and improve its sales. Zene Inc.

is working on designing new products aimed at further enhancing its genomic testing services, although specific release dates are not disclosed. Additionally, there are intentions to expand into new markets, with a focus on enhancing services to municipalities and health insurance unions outside of Japan.